Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAIR: Osimertinib plus Bevacizumab in EGFR-mutated NSCLC
NCT04988607Phase 2Unknown
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Aug 2021
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guangdong Association of Clinical Trials. Primary endpoint: Progression-Free Survival up to 3 years. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04988607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988607.